| 1761 |
LUCIOLAP |
OLAPARIB 150 MG |
FILM COATED TABLET |
BOTTLE |
INDICATED IN OVARIAN CANCER, BREAST CANCER, PANCREATIC CANCER AND PROSTATE CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1028/23 |
10-OCT-2023 |
09-OCT-2026 |
View |
| 1762 |
LUCIOSIM 80 MG |
OSIMERTINIB 80 MG |
TABLET |
BOTTLE |
TREATMENT OF NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
05 L 0971/23 |
11-MAY-2023 |
10-MAY-2026 |
View |
| 1763 |
LUCIPAC |
PACRITINIB 100 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS WITH A PLATELET COUNT BELOW 50 X 109/L |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 1337/25 |
2025-04-21 |
2030-04-20 |
View |
| 1764 |
LUCIPALBO |
PALBOCICLIB 100 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1167/24 |
21-AUG-2024 |
20-AUG-2027 |
View |
| 1765 |
LUCIPALBO |
PALBOCICLIB 125 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1162/24 |
21-AUG-2024 |
20-AUG-2027 |
View |
| 1766 |
LUCIPAZO |
PAZOPANIB 200 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT WITH ADVANCED RENAL CELL CARCINOMA, ADVANCED SOFT TISSUE SARCOMA WHO HAVE RECEIVED PRIOR CHEMOTHERAPY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1321/25 |
28-MAR-2025 |
27-MAR-2030 |
View |
| 1767 |
LUCIPEM 4.5 |
PEMIGATINIB 4.5 MG |
TABLET |
BOTTLE |
TREATMEN OF ADULT WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTASTIC CHOLANGGIOCARCINIMA WITH FIBROBLAST GROWTH |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 0997/23 |
31-JUL-2023 |
30-JUL-2026 |
View |
| 1768 |
LUCIPIRFE |
PIRFENIDONE 200 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1277/24 |
23-JAN-2025 |
22-JAN-2030 |
View |
| 1769 |
LUCIPIRTO |
PIRTOBRUTINIB 50 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY INCLUDING A BTK INHIBITOR. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1110/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
| 1770 |
LUCIPOMA |
POMALIDOMIDE 2 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS: IN COMBINATION WITH DEXAMETHASONE, FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES INCLUDING LENALIDOMIDE AND PROTEASOME INHIBITOR AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETEION OF LAST THERAPY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1281/24 |
23-JAN-2025 |
22-JAN-2030 |
View |
